Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2004

View Archived Issues

Further data on efficacy of solifenacin for overactive bladder therapy

INO-1001 ameliorates ischemia/reperfusion injury in a canine heart transplant model

FK-778 reduces expression of adhesion molecules in preclinical models of allograft rejection

Novartis presents new S1P agonists with immunomodulating properties

Novel p38 inhibitors identified at Boehringer Ingelheim

AACAP guidelines recommend Strattera as first-line therapy for ADHD

Cubane-based mGluR modulators with activity in stroke and anxiety models

Novartis claims new substance P antagonists and their use

Novel protein kinase inhibitors in early development at Aventis

Novel TGF-beta inhibitors identified by Scios researchers

New PPARalpha/PPARgamma agonists prepared and tested at Roche

European Commission approved Sanofi-Synthelabo/Aventis tie-up

First two phase III trials for ferumoxytol commence

Mycamine NDA submitted for esophageal candidiasis

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Zelos

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Therion

Curcumin effective against human retinal endothelial cell proliferation

Second stage entered in phase I study of SPL-7013

Esteve takes marketing rights to Wilex's Rencarex in Southern Europe

Zimmer Holdings completes acquisition of Implex

European approval for Velcade in multiple myeloma

Praecis and Schering AG enter Plenaxis commercialization agreement

German approval for Niaspan

Elan completes sale of Zonegran to Eisai

Bristol-Myers Squibb and Merck & Co enter global alliance for muraglitazar

Positive data for HuMax-CD4 in phase II CTCL studies

Chugai and Roche enter second research collaboration

M-40403 improves analgesic profile of morphine in phase II trial

Natalizumab reported safe and effective in pediatric multiple sclerosis

Therapeutic benefits of ruboxistaurin mesilate in patients with DPN

Adjunctive therapy with lerdelimumab after phacotrabeculectomy beneficial for IOP

Vaccines suggested as an alternative for treating glaucoma

Involvement of COX-2 and MMP-9 in nitric oxide-mediated inflammation in animal model of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...